IDEAS home Printed from https://ideas.repec.org/a/gam/jijerp/v20y2023i3p2746-d1057063.html
   My bibliography  Save this article

Economic Burden of Cervical Cancer in Bulgaria

Author

Listed:
  • Hristina Lebanova

    (Faculty of Pharmacy, Medical University-Pleven, 5800 Pleven, Bulgaria)

  • Svetoslav Stoev

    (Faculty of Pharmacy, Medical University-Pleven, 5800 Pleven, Bulgaria)

  • Emilia Naseva

    (Faculty of Public Health “Prof. Tsekomir Vodenicharov, MD, DSc”, Medical University of Sofia, 1527 Sofia, Bulgaria)

  • Violeta Getova

    (Faculty of Pharmacy, Medical University of Sofia, 1000 Sofia, Bulgaria)

  • Wei Wang

    (Center for Observational and Real-World Evidence, Merck & Co., Inc., Rahway, NJ 07065, USA)

  • Ugne Sabale

    (Center for Observational and Real-World Evidence, Merck Sharp & Dohme, 11330 Stockholm, Sweden)

  • Elina Petrova

    (Market Access, MSD, 1407 Sofia, Bulgaria)

Abstract

Bulgaria is among the European Union (EU) countries with the highest burden of cervical cancers and life expectancy below the EU average. The majority of cervical cancer cases (more than 95%) are caused by the human papillomavirus (HPV). The aim of this retrospective, cost of illness study is to identify direct healthcare costs of cervical cancer in Bulgaria from the payer perspective and to calculate indirect costs and the associated years of life lost. Costs data were sourced from the National Health Insurance Fund from January 2018 to December 2020. Years of life lost were calculated based on the country and gender-specific life expectancy. Indirect costs due to productivity loss were calculated using the human capital approach. The total treatment costs for 3540 patients with cervical cancer are EUR 5,743,657 (2018), EUR 6,377,508 (2019), and EUR 6,751,182 (2020). The costs associated with drug acquisition and administration accounted for the majority (63%) of total healthcare costs followed by hospital management costs (14%). An estimated total of 20,446 years of life were lost due to cervical cancer for the period 2018–2020. The costs of productivity losses are estimated at EUR 7,578,014. Our study showed that the economic burden of cervical cancer in Bulgaria is substantial. Focus on cervical cancer prevention via vaccination against the human papillomavirus, timely screening, early diagnosis, and higher vaccine coverage rates could reduce its economic burden in Bulgaria.

Suggested Citation

  • Hristina Lebanova & Svetoslav Stoev & Emilia Naseva & Violeta Getova & Wei Wang & Ugne Sabale & Elina Petrova, 2023. "Economic Burden of Cervical Cancer in Bulgaria," IJERPH, MDPI, vol. 20(3), pages 1-12, February.
    • Handle: RePEc:gam:jijerp:v:20:y:2023:i:3:p:2746-:d:1057063
    as

    Download full text from publisher

    File URL: https://www.mdpi.com/1660-4601/20/3/2746/pdf
    Download Restriction: no
    File URL: https://www.mdpi.com/1660-4601/20/3/2746/
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Fawziah Marra & Karine Cloutier & Bridgette Oteng & Carlo Marra & Gina Ogilvie, 2009. "Effectiveness and Cost Effectiveness of Human Papillomavirus Vaccine," PharmacoEconomics, Springer, vol. 27(2), pages 127-147, February.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Nadia Demarteau & Thomas Breuer & Baudouin Standaert, 2012. "Selecting a Mix of Prevention Strategies against Cervical Cancer for Maximum Efficiency with an Optimization Program," PharmacoEconomics, Springer, vol. 30(4), pages 337-353, April.
    2. van Ackere, Ann & Schulz, Peter J., 2020. "Explaining vaccination decisions: A system dynamics model of the interaction between epidemiological and behavioural factors," Socio-Economic Planning Sciences, Elsevier, vol. 71(C).
    3. Steffen Flessa & Dominik Dietz & Elisabete Weiderpass, 2016. "Health policy support under extreme uncertainty: the case of cervical cancer in Cambodia," EURO Journal on Decision Processes, Springer;EURO - The Association of European Operational Research Societies, vol. 4(3), pages 183-218, November.
    4. Nadia Demarteau & Bruno Detournay & Bertrand Tehard & Abdelkader El Hasnaoui & Baudouin Standaert, 2011. "A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer," International Journal of Public Health, Springer;Swiss School of Public Health (SSPH+), vol. 56(2), pages 153-162, April.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:gam:jijerp:v:20:y:2023:i:3:p:2746-:d:1057063. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: MDPI Indexing Manager (email available below). General contact details of provider: https://www.mdpi.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.